A. Uluslararası hakemli dergilerde yayımlanan makaleler:

A01. Dobrucalı A, Tuncer M, Eralp Y, Göksel S, Altın M, Dinç İ, “One-day high dose combined therapy of H. Pylori infection,”  Dig Dis Sci, 42(10), 2169-70 (letter) (1997).
A02. Dobrucali A, Canbakan B, Canbakan M, Bagatur N, Uzunismail H, Eralp Y, Akün E,Göksel S, Yurdakul I, Oktay E, “Metaanalyse zur feststellung der keimeradizierenden potenz  verschiedener therapieschemata bei H. Pylori infektion,” Wiener Medizinische Wochenschrift, 148(20), 464-8 (1998).
A03. Taş F, Aydıner A, Topuz E, Çamlıca H, Saip P, Eralp Y, “Factors influencing the distribution of metastases and survival in extensive disease small cell lung cancer,” Acta Oncol, 38(8),1011-5 (1999).
A04. Eralp Y, Bavbek S, Başaran M, Kaytan E, Yaman F, Eralp L, Özger H, Bilgiç B, Kalaycı G, Onat H, “Prognostic factors and survival in patients with metastatic soft tissue sarcoma,” J Balkan Union Oncol, 5,281-6 (2000).
A05. Topuz E, Aydıner A, Saip P, Eralp Y, Taş F, Salihoğlu Y, Berkman S, Bengisu E, “Correlations of serum CA-125 levels and computerized CT imaging with laparotomic findings following intraperitoneal chemotherapy in patients with ovarian cancer,” Eur J Gyn Oncol, 2(6),599-602 (2000).
A06. Özçelik D, Eralp Y, Öztekin G, Dursun Ş, Uzunismail H, “The impact of penicillamine and zinc inhepatic and brain tissues of copper-overloaded rats,” Trace Elem Elect, 18(1), 34-38 (2001).
A07. Eralp Y, Aydıner A, Taş F, Saip P, Topuz E, “Stevens-Johnson Syndrome in a patient receiving anticonvulsant therapy during cranial irradiation,” Am J Clin Oncol, 24(4),347-50 (2001).
A08. Topuz E, Eralp Y, Saip P, Aydıner A, Taş F, Salihoğlu Y, Berkman S, Bengisu E, “The efficacy of a combination chemotherapy including intraperitoneal cisplatinum and mitoxantrone with intravenous ifosfamide in patients with FIGO stage Ic ovarian carcinoma,” Eur J Gynaecol Oncol, 22(1),70-73 (2001).
A09. Tas F, Basaran M, Aydiner A, Eralp Y, Topuz E, “5-fluorouracil-induced balanitis in a patient with oesophageal carcinoma,” Clin Oncol (R Coll Radiol),13(3),170-171 (2001).
A10. Salihoglu Y, Bilir A, Aydiner A, Erkan M, Tuzlali S, Eralp Y, “Thymidine labeling index in epithelial ovarian cancer,” Int J Gynaecol Obstet,75(2),171-6 (2001).
A11. Basaran M, Bavbek ES, Sakar B, Eralp Y, Alici S, Tas F, Yaman F, Dogan O O, Camlica H, Onat H, “Treatment of aggressive non-Hodgkin's lymphoma with dose-intensified epirubicin in combination of cyclophosphamide, vincristine, and prednisone (CEOP-100): a phase II study,” Am J Clin Oncol,24(6),570-5 (2001).
A12. Topuz E, Eralp Y, Aydiner A, Saip P, Tas F, Yavuz E, Salihoglu Y, “The role of chemotherapy in malignant mixed mullerian tumors of the female genital tract,” Eur J Gynaecol Oncol,22(6),469-72 (2001).
A13. Tas F, Eralp Y, Basaran M, Sakar B, Alici S, Argon A, Bulutlar G, Camlica H, Aydiner A, Topuz E, “Anemia in oncology practice: relation to diseases and their therapies,” Am J Clin Oncol,25(4),371-9 (2002).
A14. Eralp Y, Bavbek S, Basaran M, Kaytan E, Yaman F, Bilgic B, Darendeliler E, Onat H, “Prognostic factors and survival in late adolescent and adult patients with small round cell tumors” Am J Clin Oncol,25(4), 418-24 (2002).
A15. Alici S, Eralp Y, Saip P, Argon A, Basaran M, Topuz E, Aydiner A, “Clinical characteristics of gestational trophoblastic disease at a single institute,” Tohoku J Exp Med,197(2),95-100 (2002).
A16. Alici S, Bavbek SE, Kaytan E, Basaran M, Eralp Y, Onat H, “Aggressive non-Hodgkin's lymphoma treated at the Institute of Oncology, Istanbul: treatment, outcome, and prognostic factors,” Am J Clin Oncol, 25(5),502-8 (2002).
A17. Alıcı S, Bavbek S, Eralp Y, Argon A, Başaran M, Aydıner A, Tuzlalı S, Topuz E, Onat H, “An atypical presentation of metastatic gestational choriocarcinoma with maxillary sinus and subcutaneous involvement; Report of a case with literature review”, J BUON, 7:373-376 (2002).
A18. Alici S, Bavbek SE, Kaytan E, Eralp Y, Onat H, “Prognostic factors in localized aggressive non-Hodgkin's lymphoma,” Am J Clin Oncol, 26(1),1-5 (2003).
A19. Eralp Y, Aydıner A,Kizir A,Kaytan E,Oral EN,Topuz E, “Resectable thymoma: treatment outcome and prognostic factors in the late adolescent and adult age group,” Cancer Investigation 21(5),737-43 (2003).
A20. Kaytan E, Yaman F, Cosar R, Eralp Y, Saip P, Darendeliler E. Prognostic factors in localized soft-tissue sarcomas. Am J Clin Oncol. 2003 Aug;26(4):411-5.
A21. Alici S, Saip P, Eralp Y, Aydiner A, Topuz E. Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC). Am J Clin Oncol. 2003 Aug;26(4):358-62.
A22. Eralp Y, Saip P, Sakar B, Tas F, Aydiner A, Topuz E, “Efficacy of cisplatin and cyclophosphamide combination for recurrent and metastatic carcinoma of the uterine cervix,” Eur J Gynaecol Oncol, 24(3-4):323-6 (2003).
A23. Eralp Y, Saip P, Sakar B, Kucucuk S, Aydiner A, Dincer M, Aslay I, Topuz E, “Prognostic factors and survival in patients with metastatic or recurrent carcinoma of the uterine cervix,”  Int J Gynecol Cancer, 13(4):497-504 (2003).
A24. Bilir A, Ozmen V, Kecer M, Eralp Y, Cabioglu N, Agizhali B, Camlica H, Aydiner A. Thymidine labeling index: prognostic role in breast cancer. Am J Clin Oncol. 2004 Aug;27(4):400-6.
A25. Eralp Y, Wang X, Wang JP, Maughan MF, Polo JM, Lachman LB.  Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model. Breast Cancer Res. 2004;6(4):R275-83. Epub 2004 Apr 07.
A26.Topuz E, Eralp Y, Saglam S, Saip P, Aydiner A, Berkman S, Yavuz E. Efficacy of intraperitoneal cisplatin as consolidation therapy in patients with pathologic complete remission following front-line therapy for epithelial ovarian cancer. Consolidative intraperitoneal cisplatin in ovarian cancer. Gynecol Oncol. 2004 Jan;92(1):147-51.
A27. Oral EN, Aydiner A, Eralp Y, Topuz E. Induction and concurrent chemotherapy with concomitant boost radiotherapy in non-small cell lung cancer. Med Oncol. 2005;22(4):367-74.
A28.Gonzalez-Angulo AM, Broglio K, Kau SW, Eralp Y, Erlichman J, Valero V, Theriault R, Booser D, Buzdar AU, Hortobagyi GN, Arun B. Women age < or = 35 years with primary breast carcinoma: disease features at presentation.Cancer. 2005 Jun 15;103(12):2466-72.
A29. Tas F, Ustuner Z, Can G, Eralp Y, Camlica H, Basaran M, Karagol H, Sakar B,Disci R, Topuz E. The prevalence and determinants of the use of complementary and alternative medicine in adult Turkish cancer patients.
Acta Oncol. 2005;44(2):161-7.
A30. Karagol H, Saip P, Uygun K, Caloglu M, Eralp Y, Tas F, Aydiner A, Topuz E. The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer. Med Oncol. 2007;24(1):39-43.
A31. Litton JK, Eralp Y, Gonzalez-Angulo AM, Broglio K, Uyei A, Hortobagyi GN, Arun B.Multifocal breast cancer in women < or =35 years old. Cancer. 2007 Oct 1;110(7):1445-50.
A32. Pinar Saip; Zeki Aydin; Sinan Berkman; Erkan Topuz. Leptomeningeal dissemination of ovarian carcinoma through a ventriculoperitoneal shunt. Gynecol Oncol Gynecol Oncol. 2008 Jan;108(1):248-50.
A33. Eralp Y, Derin D, Ozluk Y, Yavuz E, Guney N, Saip P, Muslumanoglu M, Igci A, Kucucuk S, Dincer M, Aydiner A, Topuz E. MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple negative breast cancer. Ann Oncol 2007 Ann Oncol. 2008 Apr;19(4):669-74.
A34. Cicin I, Saip P, Eralp Y, Selam M, Topuz S, Ozluk Y, Aydin Y, Topuz E. Ovarian carcinosarcomas: Clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum. Gynecol Oncol. 2008 108 (1):136-40.
A35. Eralp Y, Saip P, Aydin Z, Berkman S, Topuz E. Leptomeningeal dissemination of ovarian carcinoma through a ventriculoperitoneal shunt. Gynecol Oncol. 2008 Jan;108(1):248-50.
A36. Deligezer U, Eralp Y, Akisik EE, Akisik EZ, Saip P, Topuz E, Dalay N. Size distribution of circulating cell-free DNA in sera of breast cancer patients in the course of adjuvant chemotherapy. Clin Chem Lab Med. 2008;46(3):311-7.
A37. Derin D, Eralp Y, Guney N, Ozlük Y, Topuz E.Ovarian carcinoma with simultaneous breast and rectum metastases. Onkologie. 2008 Apr;31(4):200-2.
A38. Saip P, Cicin I, Eralp Y, Kucucuk S, Tuzlali S, Karagol H, Aslay I, Topuz E. Factors affecting the prognosis of breast cancer patients with brain metastases. Breast. 2008 Oct;17(5):451-8.
A39. Eralp Y, Smith TL, Altundağ K, Kau SW, Litton J, Valero V, Buzdar A,Hortobagyi GN, Arun B.Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger. J Cancer Res Clin Oncol. 2009 Jan;135(1):141-8.
A40. Derin D, Eralp Y, Ozluk Y, Yavuz E, Guney N, Saip P, Igci A, Ozmen V, Kücücük S, Aslay I, Aydiner A, Topuz E. Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer. Cancer Invest. 2008 26(7):671-9.
A41. Deligezer U, Eralp Y, Akisik EZ, Akisik EE, Saip P, Topuz E, Dalay N. Effect of adjuvant chemotherapy on integrity of free serum DNA in patients with breast cancer. Ann N Y Acad Sci. 2008 Aug;1137:175-9.
A42. Saip P, Cicin I, Eralp Y, Karagol H, Kucucuk S, Cosar Alas R, Yavuz E, Dincer M, Saglam E, Topuz E.Identification of patients who may benefit from the prophylactic cranial radiotherapy among breast cancer patients with brain metastasis. J Neurooncol. 2008 Dec 20. (e-print).
A43. Karagol H, Saip P, Eralp Y, Topuz S, Berkman S, Ilhan R, Topuz E. Factors related to recurrence after pathological complete response to postoperative chemotherapy in patients with epithelial ovarian cancer. Tumori. 2009 Mar-Apr;95(2):207-11.
A44. Cicin I, Saip P, Guney N, Eralp Y, Ayan I, Kebudi R, Topuz E. Yolk sac tumours of the ovary: evaluation of clinicopathological features and prognostic factors. Eur J Obstet Gynecol Reprod Biol. 2009 Oct;146(2):210-4. Epub 2009 May 5.
A45. Cicin I, Eralp Y, Saip P, Ayan I, Kebudi R, Iyibozkurt C, Tuzlali S, Gorgun O, Topuz E. Malignant ovarian germ cell tumors: a single-institution experience. Am J Clin Oncol. 2009 Apr;32(2):191-6. PubMed PMID: 19307952.
A46. Aydiner A, Toker A, Sen F, Bicakci E, Saglam EK, Erus S, Eralp Y, Tas F, Oral EN, Topuz E, Dilege S. Association of clinical and pathological variables with survival in thymoma. Med Oncol. 2011 Nov 6. PubMed PMID: 22057358.
A47. Keskin S, Muslumanoglu M, Saip P, Karanlık H, Guveli M, Pehlivan E, Aydoğan F, Eralp Y, Aydıner A, Yavuz E, Ozmen V, Igci A, Topuz E. Clinical and pathological features of breast cancer associated with the pathological complete response to anthracycline-based neoadjuvant chemotherapy. Oncology. 2011;81(1):30-8. Epub 2011 Sep 9. PubMed PMID: 21912195.
A48. Saip R, Sen F, Vural B, Ugurel E, Demirkan A, Derin D, Eralp Y, Camlica H, Ustuner Z, Ozbek U. Glutathione S-transferase P1 polymorphisms are associated with time to tumor progression in small cell lung cancer patients. J BUON. 2011 Apr-Jun;16(2):241-6. PubMed PMID: 21766492.
A49. Aydiner A, Sen F, Saglam EK, Oral EN, Eralp Y, Tas F, Toker A, Dilege S.Induction   with triweekly docetaxel and cisplatin followed by concomitant chemoradiotherapy with or without surgery in stage III non-small-cell lung cancer: a phase II study. Clin Lung Cancer. 2011 Sep;12(5):286-92. doi: 10.1016/j.cllc.2011.03.030. Epub 2011 May 8. PubMed PMID: 21729649.
A50. Keskin S, Muslumanoglu M, Saip P, Karanlık H, Guveli M, Pehlivan E, Aydoğan F, Eralp Y, Aydıner A, Yavuz E, Ozmen V, Igci A, Topuz E. Clinical and pathological
features of breast cancer associated with the pathological complete response to anthracycline-based neoadjuvant chemotherapy. Oncology. 2011;81(1):30-8.
A51. Aydiner A, Toker A, Sen F, Bicakci E, Saglam EK, Erus S, Eralp Y, Tas F, Oral EN, Topuz E, Dilege S. Association of clinical and pathological variables with survival in thymoma. Med Oncol. 2012 Sep;29(3):2221-8.
A52. Eralp Y, Keskin S, Akışık E, Akışık E, İğci A, Müslümanoğlu M, Yılmaz S, Tunacı M, Çamlıca H, Tuzlalı S, Saip P, Dalay N, Özmen V, Topuz E. Predictive role of midtreatment changes in survivin, GSTP1, and topoisomerase 2α expressions for pathologic complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Am J Clin Oncol. 2013 Jun;36(3):215-23.
A53.  Altundag K, Dizdar O, Ozsaran Z, Ozkok S, Saip P, Eralp Y, Komurcu S, Kuzhan O, Ozguroglu M, Karahoca M. Phase II study of loading-dose ibandronate treatment in patients with breast cancer and bone metastases suffering from moderate to severe pain. Onkologie. 2012;35(5):254-8.
A54. Ciblak MA; Grip Platformu. Influenza vaccination in Turkey: prevalence of risk groups, current vaccination status, factors influencing vaccine uptake and steps
taken to increase vaccination rate. Vaccine. 2013 Jan 7;31(3):518-23.
A55. Yildiz I, Tas F, Kilic L, Sen F, Saip P, Eralp Y, Keskin S, Karabulut S,Ciftci R, Serilmez M, Yasasever V, Aydiner A. A high serum level of M65 is associated with tumour aggressiveness and an unfavourable prognosis for epithelial ovarian cancer. Cancer Chemother Pharmacol. 2013 Aug;72(2):437-44.
A56. Saip P, Eralp Y, Sen F, Karaca H, Ozkan M, Cetin B, Benekli M, Kucukoner M,Isikdogan A, Un O, Basaran G, Onur H. Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: a multicentric Turkish Oncology Group (TOG) trial. Breast. 2013 Oct;22(5):628-33.
A57. Içli F, Altundağ K, Akbulut H, Paydaş S, Başaran G, Saip P, Doğu GG, Eralp Y, Uslu R, Sevinç A, Onur H, Mandel NM, Sezgin C, Altınbaş M, Güler N, Işıkdoğan A, Gökmen E, Uygun K, Ustüner Z, Yaren A, Demirkan B, Coşkun U, Ata A, Ozkan M, Arican A. Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG). Breast Cancer. 2013 Dec 12.
A58. Karabulut S, Akşit E, Tas F, Ciftci R, Aydiner A, Yildiz I, Keskin S, Eralp Y,Yasasever CT, Vatansever S, Disci R, Saip P. Is there any diagnostic value of serum protease-activated receptor-1 (PAR1) levels on determination of epithelial  ovarian carcinoma? Tumour Biol. 2014 Jan 5.
A59. Gezer U, Keskin S, Iğci A, Tükenmez M, Tiryakioğlu D, Cetinkaya M, Dişci R, Dalay N, Eralp Y. Abundant circulating microRNAs in breast cancer patients fluctuate considerably during neoadjuvant chemotherapy. Oncol Lett. 2014 Aug;8(2):845-848.

B. Uluslararası bilimsel toplantılarda sunulan ve bildiri kitabında (Proceedings) basılan bildiriler:

B01. Ferhanoğlu B, Eralp Y, Arun B, Soysal T, Avanoğlu Y, Ülkü B, Akman N, Başlar Z: Cytokines in multiple myeloma. Proc. 13th Metting of the International Society of Hematology (European and African Division), 912, İstanbul, Turkey, 1995.
B02. Arun B, Eralp Y, Ferhanoğlu B, “Soluble IL-2 receptors in hematologic malignancies,” Proc. 13th Metting of the International Society of Hematology (European and African Division), 619, İstanbul, Turkey, 1995.
B03. Eralp Y, Ferhanoğlu B,, Demir M, Hız M, Tüzüner N, Akman N, Türemen E: Primary lymphoma of bone. Proc. 13th Metting of the International Society of Hematology (European and African Division), 904, İstanbul, Turkey, 1995.
B04. Karter Y, Tunçkale A, Köksal S, Eralp Y, Seyahi N, Yaldıran A, Öztürk E, “The antihypertensive effect of doxazocine on the arterial system; Change in resistance and arterial compliance,” Proc. European Federation of Internal Medicine, 1st Congress, Vol 8 (Suppl 1), P 265, Maastricht, Netherlands,1997.
B05. Karter Y, Tunçkale A, Eralp Y, Uzun H, Aydın S, Seyahi N, Yaldıran A, Öztürk E,  “Cytokines interrelationships and their association with acute phase proteins in Hodgkin's Disease,” Proc. European Federation of Internal Medicine, 1st Congress, Vol 8 (Suppl 1), P 376, Maastricht, Netherlands,1997.
B06. Karter Y, Uzun H, Aydın S, Tunçkale A, Eralp Y, Seyahi N, Yaldıran A, Öztürk E, “Cytokines interrelationships and their association with acute phase proteins in Rheumatoid Arthritis,” Proc. European Federation of Internal Medicine, 1st Congress, Vol 8 (Suppl 1), P 372, Maastricht, Netherlands,1997.
B07. Topuz E, Alıcı S, Taş F, Eralp Y, Bulutlar G, Saip P, Aydıner A, “Clinical characteristics of gestational trophoblastic disease (GTD) at a single institute”, 9th International Congress on Anti-cancer Treatment, PP15 ,Paris, France, 1999.
B08. Alıcı S, Aydiner A, Eralp Y, Bulutlar G, Topuz E, “An atypical presentation of a case with metastatic choriocarcinoma with maxillary sinus and subcutaneous tissue involvement”, Proc. 9th  International Congress on Anti-cancer Treatment, PP16, Paris, France, 1999.
B09. Aydıner A, Topuz E, Eralp Y, Taş F, Saip P, “A case with multiple pulmonary nodules and renal vasculitis,” 10th International Congress on Anti-cancer Treatment, P242 ,Paris, France, 2000.
B10. Eralp Y, Bavbek S, Başaran M, Kaytan E, Yaman F, Bilgiç B, Darendeliler E, Onat H, “Prognostic factors and survival in adult patients with small round cell tumors,” Proc. 25th  Meeting of the European Society of Medical Oncology, Vol 11(Suppl 4), P 576, Hamburg, Germany, 2000.
B11. Topuz E, Eralp Y, Aydıner A, Saip P, Taş F, Salihoğlu Y, “The role of chemotherapy in malignant mixed mullerian tumors of the female genital tract,” Proc. 25th  Meeting of the European Society of Medical Oncology, P 354, Hamburg, Germany, 2000.
B12. Bavbek S, Başaran M, Saip S, Eralp Y, Sakar B, Onat H, “Neurologic late toxicity in testicular cancer patients treated with bleomycin, etoposide and cisplatin (bep) combination chemotherapy”, Proc. 25th  Meeting of the European Society of Medical Oncology, P 345, Hamburg, Germany, 2000.
B13. Özger H, Eralp Y, Kaytan E, Eralp L, Yaman F, Bavbek S, Başaran M, Bilgiç B, Darendeliler E, Onat H, “Prognostic factors and survival in patients with non-metastatic soft tissue sarcoma of the extremities,” Proc. Asia-Pacific Musculosceletal Tumor Association 3rd  Meeting, P33, Hong Kong, 2000.
B14. Eralp Y, Toptani S, Tas F, Camlica H, Topuz E, “Circulating Her-2/neu levels in patients with melanoma”, Proc. AACR-NCI-EORTC International Conference, 151-152, P746, Miami, USA, 2001.
B15. Topuz E, Aydıner A, Eralp Y, Saip P, Taş F, Salihoğlu Y, “Efficacy of paclitaxel in combination with intraperitoneal cisplatinum in patients with advanced ovarian cancer”, Proc. 11th the European Cancer Conference, Vol 37(Suppl 6), P 1196, Lisbon, Portugal, 2001.
B16. Eralp Y, Aydıner A,Kizir A,Kaytan E,Oral EN,Topuz E, “Resectable thymoma: treatment outcome and prognostic factors in the late adolescent and adult age group,” Proc. 12th the European Cancer Conference, Eur J Cancer, Vol 1(No 5), P130, Copenhagen, Denmark, 2003.
B17. Eralp Y, Smith TL, Kau SW, Valero V, Buzdar A, Hortobagyi GN, Arun B. Body mass index (BMI) is a predictor for response to neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger. JOURNAL OF CLINICAL ONCOLOGY 22 (14): 27S-27S 600 Suppl. S, JUL 15 2004, Abs 600, Annual ASCO Meeting 2004, June 5-8, 2004, New Orleans, Lousiana, USA.
B18. Aydiner A, Topuz E, Eralp Y, Kaytan E, Oral EN, Kizir A . Induction chemotherapy with carboplatin and weekly paclitaxel followed by concomitant chemoradiation in locally advanced non-small cell lung cancer.  JOURNAL OF CLINICAL ONCOLOGY 22 (14): 683S-683S 7270 Suppl. S, JUL 15 2004, Abs. 7270, Annual ASCO Meeting 2004, June 5-8, 2004, New Orleans, Lousiana, USA.
B19.  Topuz E, Tas F, Argon A, Yildiz DD, Oguz H, Yasasever V, Eralp Y, Aydiner A . Serum levels of leptin and proinflammatory cytokinesin advanced stage non-small cell lung cancer. JOURNAL OF CLINICAL ONCOLOGY 23 (16): 189S-189S Part 1 Suppl. S, JUN 1 2005, Abst 2594, Annual ASCO Meeting 2005, May 14-17, 2005, Orlando, Fl, USA.
B20. Karagol H, Saip P, Uygun K, Caloglu M. , Eralp Y, Tas F, Aydiner A , Topuz E. The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer. ANNALS OF ONCOLOGY 17: 174-174 Suppl. 9, 2006; P551, 31th ESMO Congress, 29 Sept-3 Oct 2006, Istanbul, TURKEY.
B21. Karagol H, Saip P, Uygun K, , Eralp Y, Topuz S, Berkman S, Ilhan R, Topuz E. Factors related with recurrence after complete pathologic response to post- operative chemotherapy in patients with epithelial ovarian cancer. P553, ANNALS OF ONCOLOGY 17: 174-174 Suppl. 9, 2006. 31th ESMO Congress, 29 Sept-3 Oct 2006, Istanbul, TURKEY.
B22. Saglam EK, Aydiner A, Sakallioglu B, Ozturk B, Eralp Y, Saip P, Oral EN, Kizir A, Topuz E. Induction chemotherapy followed by chemoradiotherapy in patients with stage IIIA-B non-small cell lung cancer (NSCLC). P771, ANNALS OF ONCOLOGY 17: 229-229 Suppl. 9, 2006, 31th ESMO Congress, 29 Sept-3 Oct 2006, Istanbul, TURKEY.
B23. Eralp Y, Duygu Derin, Yasemin Ozluk, Ekrem Yavuz, Nese Guney, Pinar Saip, Mahmut Muslumanoğlu, Abdullah İgci, Seden Kucucuk, Maktav Dincer, Adnan Aydiner and Erkan Topuz. “MAPK expression is associated with poor outcome in patients with hormone receptor negative breast cancer.” Proc 30th Annual San Antonio Breast Cancer Symposium. P 6025, Dec 13-16, 2007, San Antonio, TX, USA.
B24. Özmen V, Müslümanoğlu M, İğci A, Canbay E, Özçınar B, Mudun A, Eralp Y, Saip P, Tuzlali S, Dinçer M, Dağoğlu T, Keçer M, Parlak M. Is the sentinel lymph node biopsy accurate for patients with initially clinically axilla-positive locally advanced breast cancer after neoadjuvant chemotherapy? Cancer Research 69 (2):337 S-338S, 2009; 31th Annual San Antonio Breast Cancer Symposium, Dec 10-14, 2008, San Antonio, TX, USA.
B25. Eralp Y, Derin D, Ozluk Y, et al. MAPK expression is associated with poor outcome in patients with hormone receptor negative breast cancer.  30th Annual San Antonio Breast Cancer Symposium, DEC 13-16, 2007 San Antonio, TX;BREAST CANCER RESEARCH AND TREATMENT   Volume: 106   Pages: S255-S255  Supplement: Suppl. 1   Published: DEC 2007
B26. Deligezer U, Eralp Y, Akisik EZ, et al.Effect of adjuvant chemotherapy on integrity of free serum DNA in patients with breast cancer . 5th International Conference on Circulating Nucleic Acids in Plasma and Serum, AUG 23-27, 2007 Moscow, RUSSIA;CIRCULATING NUCLEIC ACIDS IN PLASMA AND SERUM; ANNALS OF THE NEW YORK ACADEMY OF SCIENCES   Volume: 1137   Pages: 175-179   Published: 2008
B27. Basaran G, Okkan S, Caglar H, et al.Immunohistochemically Defined T1N0 Breast Cancer Subgroups Have Different Clinical Outcomes. A Retrospective Turkish Oncology Group Study. 32nd Annual San Antonio Breast Cancer Symposium, DEC 09-13, 2009 San Antonio, TX. CANCER RESEARCH   Volume: 69   Issue: 24   Pages: 701S-701S   Supplement: Suppl. 3   Published: DEC 15 2009

D. Ulusal hakemli dergilerde yayımlanan makaleler:

D01. Eralp Y, Diri E, Görpe U, Ülkü B, “Ağır anemi ile seyreden bir Werner Sendromlu hasta: olgu bildirisi”, Cerrahpaşa Tıp Fak Dergisi, 250, 429-33 (1994).
D02. Uzunismail H, Eralp Y, Karabulut L, Bal K, Tuncer M, Sander E, İşcan M, Çelik A, Dobrucalı A, Yurdakul İ, Altın M, Oktay E, Dinç İ, “İmmunproliferatif barsak hastalığı”, Endoskopi, 5, 119-27 (1994).
D03. Eralp Y, Özder A, Karahasanoğlu T, Çubukçu A, Ekinci A, Çağlar N, Pusane A, “Koroner anjiografi sonrası gelişen bir mezenter embolili olgu bildirisi”, Türk Kardiyoloji Derneği Arşivi, 22, 407-9 (1994).
D04. Dobrucalı A, Tuncer M, EralpY, Bal K, Yurdakul İ, Altın M, Dinç İ, Aşçıoğlu F, “Fecal and circulating TNF-a measurement for assessment of disease activity in inflammatory bowel disease”, Türk Gastroenteroloji Dergisi, 5, 461-4 (1994).
D05. Ferhanoğlu B, Eralp Y, Hız M, Tüzüner N, Akman N, “Primer kemik lenfomalı üç olgu sunumu”, Cerrahpaşa Tıp Fak Dergisi, 26, 101-4 (1995).
D06.Tunçkale A, Karter Y, Eralp Y, “Kronik yorgunluk Sendromu”, Sendrom, 10 (4), 38-44 (1998).
D07. Eralp Y, Davutoğlu C, Uzunismail H, Oktay E, “Efficacy of combination therapy with omeprazole, amoxicillin ve clarithromycin for the treatment of patients with H. Pylori associated gastritis and duodenal ulcer disease”, Türk Gastroenteroloji Dergisi, 10(1), 27-31 (1999).
D08. Bağatur N, Eralp Y, Çelik A, Dobrucalı A, Bal K, Tuncer M, Göksel S, Uzunismail H, Oktay E, “Evaluation of chronic gastritis in patients with H. Pylori associated gastritis, gastroduodenitis and duodenal ulcer disease”, Türk Gastroenteroloji Dergisi, 10(1),32-55 (1999).
D09.  Eralp Y, Dobrucalı A, Bağatur N, Çelik A, Davutoğlu C, Tuncer M, Bal K, Göksel S, Uzunismail H, Yurdakul İ, Oktay E, “A comparison of lansoprazole and omeprazole based triple combinations for the treatment of Helicobacter pylori associated gastritis and peptic ulcer”, Türk Gastroenteroloji Dergisi, 11 (1), 25-29 (2000).
D10. Eralp Y, Bavbek S, Başaran M, Öner D, Çamlıca H, Kaytan E, Darendeliler E, Onat H, “Survival and prognostic factors in patients with Hodgkin’s disease”, Türk Hematoloji Onkoloji Dergisi, 10 (3), 119-25 (2000).
D11. Onat H, Eralp Y, “Meme kanserinin tedavisinde aromataz inhibitörleri”, Hematoloji-Onkoloji, 2(3): 239-50 (2000).
D12. Eralp Y. Metastatik Her-2/neu pozitif meme kanserinde trastuzumab sonrası progresyon: İkinci seçim tedavi ve ötesi. Meme Sağlığı Dergisi 2009 5 (1):3-8.

E. Ulusal bilimsel toplantılarda sunulan ve bildiri kitaplarında basılan bildiriler:

E01. Bağatur N, Dobrucalı A, Davutoğlu C, Çelik A, Hamşioğlu F, Akün E, Eralp Y, Göksel S, Bal K, Tuncer M, Yurdakul İ, Uzunismail H, Oktay E, “CTF İç Hastalıkları Kliniği 1995-96 H. Pylori eradikasyon metaanalizi”, 13. Ulusal Gastroenteroloji Kongresi, Cilt 7 (Suppl 1) 16, Antalya, 1996.
E02. Bağatur N, Eralp Y, Çelik A, Dobrucalı A, Bal K, Tuncer M, Göksel S, Uzunismail H, Oktay E., “H. Pylori’ye bağlı gastrit, gastroduodenit ve duodenal ülseli hastalarda kronik gastritin değerlendirilmesi”, 14. Ulusal Gastroenteroloji Kongresi, Cilt 8 (Suppl 1) 10, Mersin, 1997.
E03. Eralp Y, Dobrucalı A, Bağatur N, Çelik A, Davutoğlu C, Tuncer M, Göksel S, Uzunismail H, Yurdakul İ, Oktay E., “H. Pylori’ye bağlı gastrit ve duodenal ülserli hastalarda lansoprazol veya omeprazol içeren iki farklı tedavinin karşılaştırılması”, 14. Ulusal Gastroenteroloji Kongresi, Cilt 8(Suppl 1) P 206, Mersin,1997.
E04. Özçelik D, Eralp Y, Dursun Ş, Öztekin GE, Uzunismail H., “Penisilamin ve çinko sülfatın yüksek dozda bakır verilen sıçanlarda karaciğer ve beyin dokusu bakır düzeyine etkisi”, 14. Ulusal Gastroenteroloji Kongresi, Cilt 9 (Suppl 1) P 380, İstanbul, 1998.
E05. Başaran M, Uygun K, Alıcı S, Eralp Y, Saip P, Bavbek S, Onat H., “Solid tümörlü hastalarda febril nötropeni”, 3. Febril Nötropeni Sempozyumu, P 21, Antalya,1999.
E06. Eralp Y, Bavbek S, Başaran M, Uygun K, Kaytan E, Darendeliler E, Onat H, “Hodgkin hastalığında sağkalım analizi ve prognostik faktörler”, 13. Ulusal Kanser Kongresi, P 45, Antalya, 1999.
E07. Taş F, Eralp Y, Aydıner A, Saip P, Çamlıca H, Topuz E., “Yaygın küçük hücreli akciğer kanserinde metastaz dağılımı ve sağkalımı etkileyen faktörler”, 13. Ulusal Kanser Kongresi, P 200, Antalya, 1999.
E08. Uygun K, Bavbek S, Başaran M, Eralp Y, Bilgiç B, Eralp L, Özger H, Onat H., “Lokal evre osteosarkom tedavisinde yüksek doz metotrexat tedavisisinin uygulanılabilirliği ve toksisitesi”, 13. Ulusal Kanser Kongresi, P 302, Antalya, 1999.
E09. Taş F, Karagöl H, Üstüner Z, Yazar A, Can G, Çamlıca H, Eralp Y, Başaran M, Şakar B, Dişçi R, “Türk kanser hastalarında tamamlayıcı ve alternatif tıp yöntemlerinin kullanım sıklığı ve belirleyicileri”, 15. Ulusal Kanser Kongresi, P 112, Antalya, 2003.
E10. Topuz E, Kaytan E, Saip P, Eralp Y, Sönmezoğlu K, Aydıner A, “Over kanserleri yinelemelerinde CA 125, bilgisayarlı tomografi ve PET sonuçlarının karşılaştırılması”, 15. Ulusal Kanser Kongresi, P 138, Antalya, 2003.
E11. Topuz E, Eralp Y, Sağlam S, Saip P, Aydıner A, Berkman S, Yavuz E, “Primer kemoterapi sonrası tam remisyon sağlanan over kanserli hastalarda konsolidasyon tedavisi olarak intraperitoneal sisplatin tedavisinin etkinliği”, 15. Ulusal Kanser Kongresi, P 310, Antalya, 2003.
E12. Yeşil S, Yavuz E, Tuzlalı S, İlhan R, Topuz S, İyibozkurt C, Akhan S, Derin D, Güney N, Saip P, Eralp Y, Aydıner A, Taş F, Küçücük S. Tuba karsinomlarının klinikopatolojik özellikleri. 18. Ulusal Patoloji Sempozyumu 7-11 Mayıs 2006, Çaşme, Türkiye; bildiri no:336.
E13. Şahin B, Ergen A, Sağlam E, Eralp Y, Oral EN, Kizir A. Akciğer üst lob tümörlerinin retrospektif ön değerlendirmesi. 17. Ulusal Kanser Kongresi 19-23 Nisan 2007, Antalya Türkiye; bildiri no: 699.
E14. Eralp Y, Aydın Z, Berkman S, Konya D, Topuz E. Ventriküloperitoneal şantlı hastada over tümörü intraventriküler yayılımı: Olgu sunumu. 17. Ulusal Kanser Kongresi 19-23 Nisan 2007, Antalya Türkiye; bildiri no: 386.
E15. Küçücük S, Aslay I, Kemikler G, Ergen A, Okutan M, Öztürk N, Eralp Y, Özmen V, Güngel H, Töre G. Meme koruyucu cerrahi sonrası interstisyel brakiterapi ile ek doz verilen 234 hastada tedavi sonuçları: Tek merkez deneyimi.  Sözel sunum. Meme Sağlığı Dergisi 2007, 3: s21; 9. Ulusal Meme Kanseri Kongresi 3-5 Eylül 2007, Ankara.
E16. Cabioğlu N, Özçınar B, Müslümanoğlu M, Özmen V, İğci A, Dağoğlu T, Eralp Y, Aslay I, Yavuz E, Tunacı M, Aydıner A, Keçer M. Neoadjuvan kemoterapi sonrası meme koruyucu cerrahide lokal nüksü etkileyen faktörler: uzun dönem sonuçlarımız. Oral Sunum. Meme Sağlığı Dergisi 2007, 3: s40; 9. Ulusal Meme Kanseri Kongresi 3-5 Eylül 2007, Ankara.
E17. Eralp Y, Saip P, Muslumanoglu M, Igci Ai Ozmen V, Gungel H, Tuzlali S, Kucucuk S, Aydiner A, Topuz E. Antrasiklin ve taksan bazlı neoadjuvan kemoterapi kür sayısının patolojik tam yanıt ve meme koruyucu cerrahi oranları üzerine etkisi. Oral Sunum. Meme Sağlığı Dergisi 2007, 3: s43; 9. Ulusal Meme Kanseri Kongresi 3-5 Eylül 2007, Ankara.
E18. Özçınar B, Cabioğlu N, Özmen V, Müslümanoğlu M, İğci A, Keçer M, Dağoğlu T, Dinçer M, Eralp Y, Tuzlalı S, Tunacı M, Aydıner A. Lokal ileri meme kanserinde hastalıksız sağkalım ve genel sağkalımı etkileyen faktörler: uzun dönem sonuçlarımız. Oral Sunum. Meme Sağlığı Dergisi 2007, 3: s68; 9. Ulusal Meme Kanseri Kongresi 3-5 Eylül 2007, Ankara.
E19. Eralp Y, Derin D, Özlük Y, Yavuz E, Güney N, Saip P, Müslümanoğlu M, İğci A, Küçücük S, Dinçer M, Aydıner A, Topuz E. Hormona  duyarsız meme kanserinde MAPK ekspresyonunun prognostik önemi. Poster Sunum. Meme Sağlığı Dergisi 2007, 3: s80; 9. Ulusal Meme Kanseri Kongresi 3-5 Eylül 2007, Ankara.

Fa. Uluslararası bilimsel toplantılarda yayınlanan bildiri kitabında (Proceedings) basılan bildiriler:

Fa1. Topuz E, Aydıner A, Eralp Y, Uygun K, Saip P, Taş F, “Preliminary results of a phase II study with mitomycin-C and vinorelbine for the treatment of metastatic breast cancer”, Proc. ASCO 35th  Annual Meeting of the American Society of Clinical Oncology, Vol 18, 138a, Atlanta, USA, 1999.
Fa2. Alıcı S, Kaytan E, Şakar B,Bulutlar G, Eralp Y, Argon A, Aykan F, “Rectal cancer in young patients: Characteristics and outcome”, 25th ESMO Congress, a245,Hamburg,Germany, 2000.
Fa3. Alıcı S, Bulutlar G, Saip P, Eralp Y, Aydıner A, Topuz A, “Oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease”, 10th International Congress on Anti-cancer Treatment, ab013 ,Paris, France, 2000.
Fa4. Topuz E, Aydıner A, Saip P, Eralp Y, Taş F, Salihoğlu Y, Tenekeci N, “Correlation of CA 125 levels and computerized tomography imaging with laparotomic findings following intraperitoneal chemotherapy in patients with ovarian cancer”, Proc. 36th ASCO Annual Meeting of the American Society of Clinical Oncology, Vol 19, 400a, New Orleans,USA, 2000.
Fa5. Basaran M, Hafiz G, Sakar B, Eralp Y, Bavbek S, Darendeliler E, Onat H: Hearing loss in testicular cancer patients treated with bleomycin, etoposide and cisplatinum (BEP) combination chemotherapy Proc. 36th ASCO Annual Meeting of the American Society of Clinical Oncology, Vol 19, 346a, New Orleans,USA, 2000.
Fa6. Topuz E, Eralp Y, Aydiner A, Saip P, Taş F, “Intraperitoneal Chemotherapy in Patients with Peritoneal Malignant Mesothelioma”, Proc. 37th ASCO Annual Meeting of the American Society of Clinical Oncology, Vol 20, 2286a, San Francisco,USA, 2001.
Fa7. Şakar B, Başaran M, Argon A, Alıcı A, Eralp Y, Kaytan E, Buğra D, Aykan F, Topuz E, “The link between local recurrence and survival in patients with primary rectal cancer”, Proc. 38th ASCO Annual Meeting of the American Society of Clinical Oncology, Vol 21, 2372a, Orlando,USA, 2002.
Fa8. Alıcı S, Bavbek S, Kaytan E, Eralp Y, Onat H, “Prognostic factors in localized aggressive non-Hodgkin lymphoma”, Proc. 38th ASCO Annual Meeting of the American Society of Clinical Oncology, Vol 21, 2641a, Orlando,USA, 2002.
Fa9. Y. Eralp, B. Sakallioglu, S. Kucucuk, S. Tuzlali, P. Saip, A. Igci, M. Muslumanoglu, A. Aydiner, E. Topuz. Impact of adjuvant chemotherapy with respect to level of hormone receptor expression in patients with hormone responsive breast cancer: Implications for endocrine resistance. J Clin Oncol 26: 2008 (suppl; abstr 11563); . 44th ASCO Annual Meeting of the American Society of Clinical Oncology, Vol 21, 2372a, Chicago,USA, 2008.
Fa10. Eralp Y et al. The outcome of patients with triple negative breast cancer: Evidence for a favorable ethnic subgroup? The Turkish Oncology Group experience. J Clin Oncol 2009; 45th ASCO Annual Meeting of the American Society of Clinical Oncology, Chicago,USA, 2009.
Fa11. Saip P et al. Association between glutathione S-transferase P1 polymorphisms and time to tumor progression in small cell lung cancer patients. J Clin Oncol 2010; 46th ASCO Annual Meeting of the American Society of Clinical Oncology, Chicago,USA, 2010.

Fb. Yazılan ulusal kitaplar veya kitaplarda bölümler:

Fb1. Eralp Y, Aydıner A, “Yaygın küçük hücreli akciğer kanserlerinde kemoterapi”, Akciğer kanserleri: Tanı ve tedavide temel ilkeler ve uygulamalar. Ed. K. Engin, N. Özyardımcı, 183-188, Avrupa Tıp Kitapçılık, Istanbul 2001.
Fb2. Aydıner A, Eralp Y, “Kanser tanısında fizik muayene”, Kanser hastasına yaklaşım: Tanı tedavi ve takipte sorunlar. Ed. H. Onat, N. Molinas Mandel, 5-10, Nobel Tıp Kitabevleri, İstanbul 2002.
Fb3. Eralp Y, “Kanser hastasında kardiyolojik sorunlar”, Kanser hastasına yaklaşım: Tanı tedavi ve takipte sorunlar. Ed. H. Onat, N. Molinas Mandel, 165-170, Nobel Tıp Kitabevleri, İstanbul 2002.
Fb4. Eralp Y, Aydıner A, “Meme kanserinde yeni evreleme sistemi”, Meme Kanseri. Ed. E. Topuz, A. Aydıner, M. Dinçer, 132-135, Nobel Tıp Kitabevleri, İstanbul 2003.
Fb5. Aydıner A, Eralp Y, “Gebelik ve meme kanseri”, Meme Kanseri. Ed. E. Topuz, A. Aydıner, M. Dinçer, 563-570, Nobel Tıp Kitabevleri, İstanbul 2003.
Fb6. Aydıner A, Eralp Y, “Kemik metastazlarında ilaç tedavisi”, Meme Kanseri. Ed. E. Topuz, A. Aydıner, M. Dinçer, 631-641, Nobel Tıp Kitabevleri, İstanbul 2003.
Fb8.  Eralp Y, Saip P. “Rare neuroendocrine tumors”, Neuroendocrine tumors of the gastroenteropancreatic system. Ed. Yalcın S. 205-14. Ankara, 2006.

E2. BİLİMSEL ATIFLAR : 445

A01. Dobrucalı A, Tuncer M, Eralp Y, Göksel S, Altın M, Dinç İ, “One-day high dose combined therapy of H. Pylori infection,”  Dig Dis Sci, 42(10), 2169-70 (mektup) (1997). (X2)
A02. Saip P, Eralp Y, Sen F, Karaca H, Ozkan M, Cetin B, Benekli M, Kucukoner M,Isikdogan A, Un O, Basaran G, Onur H. Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: a multicentric Turkish Oncology Group (TOG) trial. Breast. 2013 Oct;22(5):628-33. (x2)
A03. Taş F, Aydıner A, Topuz E, Çamlıca H, Saip P, Eralp Y, “Factors influencing the distribution of metastases and survival in extensive disease small cell lung cancer,” Acta Oncol, 38(8),1011-5 (1999). (X18)
A04. Eralp Y, Bavbek S, Başaran M, Kaytan E, Yaman F, Eralp L, Özger H, Bilgiç B, Kalaycı G, Onat H, “Prognostic factors and survival in patients with metastatic soft tissue sarcoma,” J Balkan Union Oncol, 5,281-6 (2000). (X1)
A05. Topuz E, Aydıner A, Saip P, Eralp Y, Taş F, Salihoğlu Y, Berkman S, Bengisu E, “Correlations of serum CA-125 levels and computerized CT imaging with laparotomic findings following intraperitoneal chemotherapy in patients with ovarian cancer,” Eur J Gyn Oncol, 2(6),599-602 (2000). (X20)
A06. Özçelik D, Eralp Y, Öztekin G, Dursun Ş, Uzunismail H, “The impact of penicillamine and zinc inhepatic and brain tissues of copper-overloaded rats,” Trace Elem Elect, 18(1), 34-38 (2001). (X2)
A07. Eralp Y, Aydıner A, Taş F, Saip P, Topuz E, “Stevens-Johnson Syndrome in a patient receiving anticonvulsant therapy during cranial irradiation,” Am J Clin Oncol, 24(4),347-50 (2001). (X15)
A08. Eralp Y, Keskin S, Akışık E, Akışık E, İğci A, Müslümanoğlu M, Yılmaz S, Tunacı M, Çamlıca H, Tuzlalı S, Saip P, Dalay N, Özmen V, Topuz E. Predictive role of midtreatment changes in survivin, GSTP1, and topoisomerase 2α expressions for pathologic complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Am J Clin Oncol. 2013 Jun;36(3):215-23. (x1)
A09. Aydiner A, Toker A, Sen F, Bicakci E, Saglam EK, Erus S, Eralp Y, Tas F, Oral EN, Topuz E, Dilege S. Association of clinical and pathological variables with survival in thymoma. Med Oncol. 2012 Sep;29(3):2221-8. (x4)
A10. Aydiner A, Sen F, Saglam EK, Oral EN, Eralp Y, Tas F, Toker A, Dilege S.Induction   with triweekly docetaxel and cisplatin followed by concomitant chemoradiotherapy with or without surgery in stage III non-small-cell lung cancer: a phase II study. Clin Lung Cancer. 2011 Sep;12(5):286-92. (x3)
A11. Basaran M, Bavbek ES, Sakar B, Eralp Y, Alici S, Tas F, Yaman F, Dogan O O, Camlica H, Onat H, “Treatment of aggressive non-Hodgkin's lymphoma with dose-intensified epirubicin in combination of cyclophosphamide, vincristine, and prednisone (CEOP-100): a phase II study,” Am J Clin Oncol,24(6),570-5 (2001). (X4)
A12. Topuz E, Eralp Y, Aydiner A, Saip P, Tas F, Yavuz E, Salihoglu Y, “The role of chemotherapy in malignant mixed mullerian tumors of the female genital tract,” Eur J Gynaecol Oncol,22(6),469-72 (2001). (x2)
A13. Tas F, Eralp Y, Basaran M, Sakar B, Alici S, Argon A, Bulutlar G, Camlica H, Aydiner A, Topuz E, “Anemia in oncology practice: relation to diseases and their therapies,” Am J Clin Oncol,25(4),371-9 (2002). (X46)
A14. Eralp Y, Bavbek S, Basaran M, Kaytan E, Yaman F, Bilgic B, Darendeliler E, Onat H, “Prognostic factors and survival in late adolescent and adult patients with small round cell tumors” Am J Clin Oncol,25(4), 418-24 (2002). (X17)
A15. Alici S, Eralp Y, Saip P, Argon A, Basaran M, Topuz E, Aydiner A, “Clinical characteristics of gestational trophoblastic disease at a single institute,” Tohoku J Exp Med,197(2),95-100 (2002). (X4)
A16. Keskin S, Muslumanoglu M, Saip P, Karanlık H, Guveli M, Pehlivan E, Aydoğan F, Eralp Y, Aydıner A, Yavuz E, Ozmen V, Igci A, Topuz E. Clinical and pathological features of breast cancer associated with the pathological complete response to anthracycline-based neoadjuvant chemotherapy. Oncology. 2011;81(1):30-8. (x4)
A17. Cicin I, Eralp Y, Saip P, Ayan I, Kebudi R, Iyibozkurt C, Tuzlali S, Gorgun O, Topuz E. Malignant ovarian germ cell tumors: a single-institution experience. Am J Clin Oncol. 2009 Apr;32(2):191-6. PubMed PMID: 19307952. (x12)
A18. Alici S, Bavbek SE, Kaytan E, Eralp Y, Onat H, “Prognostic factors in localized aggressive non-Hodgkin's lymphoma,” Am J Clin Oncol, 26(1),1-5 (2003).
A19. Eralp Y, Aydıner A,Kizir A,Kaytan E,Oral EN,Topuz E, “Resectable thymoma: treatment outcome and prognostic factors in the late adolescent and adult age group,” Cancer Investigation 21(5),737-43 (2003). (X9)
A20. Kaytan E, Yaman F, Cosar R, Eralp Y, Saip P, Darendeliler E. Prognostic factors in localized soft-tissue sarcomas. Am J Clin Oncol. 2003 Aug;26(4):411-5. (x8)
A21.  Alici S, Saip P, Eralp Y, Aydiner A, Topuz E. Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC). Am J Clin Oncol. 2003 Aug;26(4):358-62. (x11)
A22. Eralp Y, Saip P, Sakar B, Tas F, Aydiner A, Topuz E, “Efficacy of cisplatin and cyclophosphamide combination for recurrent and metastatic carcinoma of the uterine cervix,” Eur J Gynaecol Oncol, 24(3-4):323-6 (2003). (x6)
A23. Eralp Y, Saip P, Sakar B, Kucucuk S, Aydiner A, Dincer M, Aslay I, Topuz E, “Prognostic factors and survival in patients with metastatic or recurrent carcinoma of the uterine cervix,”  Int J Gynecol Cancer, 13(4):497-504 (2003). (X 13)
A24. Bilir A, Ozmen V, Kecer M, Eralp Y, Cabioglu N, Agizhali B, Camlica H, Aydiner A. Thymidine labeling index: prognostic role in breast cancer. Am J Clin Oncol. 2004 Aug;27(4):400-6. (X 3)
A25.  Eralp Y, Wang X, Wang JP, Maughan MF, Polo JM, Lachman LB.  Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model. Breast Cancer Res. 2004;6(4):R275-83. Epub 2004 Apr 07. (X 38)
A26. Topuz E, Eralp Y, Saglam S, Saip P, Aydiner A, Berkman S, Yavuz E. Efficacy of intraperitoneal cisplatin as consolidation therapy in patients with pathologic complete remission following front-line therapy for epithelial ovarian cancer. Consolidative intraperitoneal cisplatin in ovarian cancer. Gynecol Oncol. 2004 Jan;92(1):147-51. (X 19)
A27. Oral EN, Aydiner A, Eralp Y, Topuz E. Induction and concurrent chemotherapy with concomitant boost radiotherapy in non-small cell lung cancer. Med Oncol. 2005;22(4):367-74. (x1)
A28.Gonzalez-Angulo AM, Broglio K, Kau SW, Eralp Y, Erlichman J, Valero V, Theriault R, Booser D, Buzdar AU, Hortobagyi GN, Arun B. Women age < or = 35 years with primary breast carcinoma: disease features at presentation.Cancer. 2005 Jun 15;103(12):2466-72. (X 13)
A29. Tas F, Ustuner Z, Can G, Eralp Y, Camlica H, Basaran M, Karagol H, Sakar B,Disci R, Topuz E. The prevalence and determinants of the use of complementary and alternative medicine in adult Turkish cancer patients. Acta Oncol. 2005;44(2):161-7. (X 36)
A30. Karagol H, Saip P, Uygun K, Caloglu M, Eralp Y, Tas F, Aydiner A, Topuz E. The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer. Med Oncol. 2007;24(1):39-43. (x11)
A31. Litton JK, Eralp Y, Gonzalez-Angulo AM, Broglio K, Uyei A, Hortobagyi GN, Arun B.Multifocal breast cancer in women < or =35 years old. Cancer. 2007 Oct 1;110(7):1445-50. (x13)
A32. Pinar Saip; Zeki Aydin; Sinan Berkman; Erkan Topuz. Leptomeningeal dissemination of ovarian carcinoma through a ventriculoperitoneal shunt. Gynecol Oncol Gynecol Oncol. 2008 Jan;108(1):248-50. (x4)
A33. Eralp Y, Derin D, Ozluk Y, Yavuz E, Guney N, Saip P, Muslumanoglu M, Igci A, Kucucuk S, Dincer M, Aydiner A, Topuz E. MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple negative breast cancer. Ann Oncol 2007 Ann Oncol. 2008 Apr;19(4):669-74. (x24)
A34. Cicin I, Saip P, Eralp Y, Selam M, Topuz S, Ozluk Y, Aydin Y, Topuz E. Ovarian carcinosarcomas: Clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum. Gynecol Oncol. 2008 108 (1):136-40. (x19)
A35. Cicin I, Saip P, Guney N, Eralp Y, Ayan I, Kebudi R, Topuz E. Yolk sac tumours of the ovary: evaluation of clinicopathological features and prognostic factors. Eur J Obstet Gynecol Reprod Biol. 2009 Oct;146(2):210-4. (x11)
A36. Deligezer U, Eralp Y, Akisik EE, Akisik EZ, Saip P, Topuz E, Dalay N. Size distribution of circulating cell-free DNA in sera of breast cancer patients in the course of adjuvant chemotherapy. Clin Chem Lab Med. 2008;46(3):311-7. (x24)
A37. Derin D, Eralp Y, Guney N, Ozlük Y, Topuz E.Ovarian carcinoma with simultaneous breast and rectum metastases. Onkologie. 2008 Apr;31(4):200-2. (x1)
A38. Saip P, Cicin I, Eralp Y, Kucucuk S, Tuzlali S, Karagol H, Aslay I, Topuz E. Factors affecting the prognosis of breast cancer patients with brain metastases. Breast. 2008 Oct;17(5):451-8. (x4)
A39. Saip P, Cicin I, Eralp Y, Karagol H, Kucucuk S, Cosar Alas R, Yavuz E, Dincer M, Saglam E, Topuz E.Identification of patients who may benefit from the prophylactic cranial radiotherapy among breast cancer patients with brain metastasis. J Neurooncol. 2008 Dec 20. (x7)
A40. Derin D, Eralp Y, Ozluk Y, Yavuz E, Guney N, Saip P, Igci A, Ozmen V, Kücücük S, Aslay I, Aydiner A, Topuz E. Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer. Cancer Invest. 2008 26(7):671-9.(x7)
A41. Deligezer U, Eralp Y, Akisik EZ, Akisik EE, Saip P, Topuz E, Dalay N. Effect of adjuvant chemotherapy on integrity of free serum DNA in patients with breast cancer. Ann N Y Acad Sci. 2008 Aug;1137:175-9. (x11)